时间:2024-09-22 12:35:24 来源:网络整理 编辑:资讯
$VTL #GDFR pic.twitter.com/FlZu2N68sy— Martin Shkreli (@MartinShkreli) August 12, 2015On Sunday, the
$VTL #GDFR pic.twitter.com/FlZu2N68sy
— Martin Shkreli (@MartinShkreli) August 12, 2015
On Sunday, the New York Times reported on the growing practice in the pharmaceutical industry of companies gobbling up the rights to old, but still vital drugs that treat life-threatening diseases and jacking up the price overnight. The staggering price hikes are then justified as the cost of providing the well-established medicines now rebranded as “specialty drugs.” One such treatment, Daraprim, used by AIDS patients (and others) to combat a potentially life-threatening parasite infection, for example, went from $13.50 to $750 a pill—overnight.
Why? On Monday, the world was introduced to the brains behind the Daraprim business strategy, former hedge fund manager and all around good guy, Martin Shkreli.
Shkreli, through his company Turing Pharmaceuticals, bought the rights to Daraprim for $55 million in August. The drug was produced for decades by GlaxoSmithKline after being approved by the F.D.A. 62 years ago. But five years ago Glaxo sold the U.S. rights, which then changed hands a couple of more times before being bought by Shkreli. During that period, the cost of Daraprim which had settled at about $1 per tablet began to steadily rise.
Advertisement Advertisement Advertisement AdvertisementPrice gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on. -H https://t.co/9Z0Aw7aI6h
— Hillary Clinton (@HillaryClinton) September 21, 2015
The latest increase could lead to a financial windfall for Turing. “Medicaid and certain hospitals will be able to get the drug inexpensively under federal rules for discounts and rebates,” the Times notes, “[b]ut private insurers, Medicare and hospitalized patients would have to pay an amount closer to the list price.” In an interview with Bloomberg TV, Shkreli went to great, generally tone-deaf lengths to assure consumers who needed the drug, but couldn’t afford it that they would not be turned away. In other words, we can all chip in and pay him for it. This is not Shkreli’s first foray into trying to wring new profits out of old medicines using the cheap shot justification that R&D’s expensive, even if the bill was footed by someone else and, presumably, already paid in full over the last six decades by American patients.
Tweet Share Share CommentApple iPod: The First 10 Years of the Ubiquitous Media Player2024-09-22 12:25
Bruley, the famous 'Queer Eye' French bulldog, has died2024-09-22 12:23
Moon apologizes for restoring tough social distancing measures2024-09-22 11:37
最懂你的乡宴!佛冈“村晚”即将在水头镇上演2024-09-22 11:28
New image shows the North Star is changing. And it has spots.2024-09-22 11:07
Twitter tests disappearing 'fleets' which sure look a lot like Stories2024-09-22 11:06
NK fires ballistic missile toward East Sea: S. Korean military2024-09-22 10:42
Misinformation about women's bodies thrives online. Meet the doctor fighting it.2024-09-22 10:40
Giant dual2024-09-22 10:29
The travel ban, black women in the labor market, and the year’s best movies.2024-09-22 10:09
Bernie Sanders’ DNC speech sounded like everyone else’s. That’s astonishing.2024-09-22 12:15
Three things we learned in the Premier League2024-09-22 11:50
800余名运动员参赛角逐多个奖项2024-09-22 11:27
1至4月 我市完成白蚁防治超10万平方米2024-09-22 11:19
Venture Missionaries2024-09-22 11:16
Woods recalls racism fight in Hall of Fame entry2024-09-22 11:16
‘Magic: The Gathering’ Time Spiral Remastered gives angels a new vintage look2024-09-22 10:57
Bleak thrills make 'Tell Me Your Secrets' an awkward bummer: TV review2024-09-22 10:53
Military prosecutors indict intel official over leaking 'black agent' info2024-09-22 10:51
贯彻实施《信访条例》 依法反映信访诉求2024-09-22 10:48